Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals there are no other effective treatment options, and symptoms can persist after discontinuing or changing antipsychotic therapy.
Interventions of Interest:
- Valbenazine (Ingrezza®, Neurocrine Biosciences, Inc)
- Deutetrabenazine (Austedo®, Teva)
- Tetrabenazine (Xenazine®)
Date of Review: December 2017
For questions or additional information, please contact firstname.lastname@example.org
2345 Commonwealth Avenue
Newton, MA 02466
The New England CEPAC convened to review ICER's evidence report assessing the clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder related to prolonged use of antipsychotic medications.